Halozyme Execs to Present at Three Major Healthcare Conferences in September — Halozyme Therapeutics, Inc.

Event summary

Halozyme's CEO Dr. Helen Torley and CFO Darren Snellgrove to participate in three investor conferences in September 2026.
Events include Wells Fargo Healthcare Conference (Sep 9), Morgan Stanley Global Healthcare Conference (Sep 15), and H.C. Wainwright Global Investment Conference (Sep 16).
Live audio webcasts available on Halozyme's Investor Relations page, with replays accessible for 90 days post-conference.
Halozyme's ENHANZE® technology has been licensed to over 15 leading pharmaceutical and biotechnology companies.
Company also developing Hypercon™ and Surf Bio's hyperconcentration technology for subcutaneous drug delivery.

The big picture

Halozyme's participation in these high-profile investor conferences underscores its strategic focus on expanding its drug delivery technology portfolio. The company's ENHANZE® technology has already demonstrated significant commercial success, with over one million patient lives touched. The addition of Hypercon™ and Surf Bio's hyperconcentration technology positions Halozyme to capture a larger share of the subcutaneous drug delivery market, a segment increasingly important as biopharmaceutical companies seek more convenient and patient-friendly administration methods.

What we're watching

Technology Adoption: How the expansion of Hypercon™ and Surf Bio's hyperconcentration technology will impact Halozyme's partnership portfolio and revenue streams.
Market Positioning: Whether Halozyme can sustain its leadership in drug delivery technology amid increasing competition in the biopharmaceutical sector.
Strategic Partnerships: The pace at which Halozyme secures new licensing agreements for its drug delivery technologies with top-tier pharmaceutical companies.